Introduction, History, Mission, SIOP & Wilms Tumor, and the SIOP Renal Tumour Study Group (RTSG)

​

The History of SIOP

​

Founded in 1969, the International Society of Paediatric Oncology was established to create a global forum where healthcare professionals treating childhood cancer could work together to improve patient outcomes. At a time when childhood cancer survival rates were considerably lower than they are today, clinicians recognised that international cooperation, shared clinical experience, and collaborative research would be essential to advancing pediatric oncology.

Over the following decades, SIOP evolved from a relatively small network of specialists into the world's largest multidisciplinary pediatric oncology organisation. Its membership now spans every major medical discipline involved in childhood cancer care, including pediatric oncology, pediatric surgery, radiation oncology, pathology, radiology, nursing, psychology, nutrition, rehabilitation, survivorship, epidemiology, and clinical research. This broad expertise enables SIOP to address every stage of the childhood cancer journey—from diagnosis and treatment through survivorship and long-term follow-up.

​

Throughout its history, SIOP has helped transform the management of childhood cancers by promoting international clinical trials, encouraging multidisciplinary care, supporting evidence-based treatment protocols, and fostering scientific collaboration between hospitals, universities, research institutes, governments, and non-governmental organisations. Many of today's internationally recognised standards for pediatric cancer treatment have been influenced by research undertaken through SIOP study groups and collaborative networks.

​

For Wilms tumor specifically, SIOP has played a defining role in establishing treatment approaches that balance excellent survival with reduced long-term treatment toxicity. The organisation's contributions have helped improve kidney preservation, reduce unnecessary radiation exposure, refine chemotherapy protocols, strengthen pathology review, and improve risk-adapted treatment planning for children around the world.

​

SIOP's Mission and Vision

​

SIOP's mission extends far beyond conducting scientific meetings. The organisation seeks to improve the lives of every child diagnosed with cancer by promoting excellence in clinical care, supporting innovative research, strengthening healthcare systems, educating healthcare professionals, and encouraging international collaboration.

​

Its work is centred on several interconnected priorities:

​

• Advancing pediatric oncology research.

• Developing internationally recognised treatment protocols.

• Supporting multidisciplinary care.

• Improving childhood cancer survival.

• Expanding healthcare professional education.

• Strengthening pediatric oncology services worldwide.

• Supporting countries with limited healthcare resources.

• Encouraging collaboration between clinicians, researchers, governments, and advocacy organisations.

• Improving survivorship and long-term quality of life.

• Reducing global inequalities in childhood cancer outcomes.

 

These priorities closely mirror the ambitions of the World Health Organization's Global Initiative for Childhood Cancer (GICC), demonstrating SIOP's commitment to ensuring that every child—regardless of geography or income—has access to safe, effective, evidence-based cancer care.

​

SIOP and Wilms Tumor

​

Among all childhood cancers, Wilms tumor represents one of SIOP's most significant areas of scientific leadership. For decades, the organisation has coordinated international research programmes that have fundamentally changed how pediatric renal cancer is diagnosed, staged, treated, and monitored.

A defining feature of the SIOP approach is the use of pre-operative chemotherapy for most children with Wilms tumor before surgical removal of the affected kidney. This strategy differs from the approach traditionally used by the Children's Oncology Group (COG), where immediate surgery has historically been more common. Both approaches are supported by extensive clinical evidence and have contributed significantly to the excellent survival rates now achieved in specialist treatment centres worldwide.

​

Rather than viewing these approaches as competing philosophies, they represent complementary evidence-based strategies that continue to inform international research and improve clinical decision-making. Through ongoing collaboration between SIOP, COG, WHO, St. Jude Children's Research Hospital, and many national pediatric oncology groups, knowledge gained from different treatment protocols continues to refine care for children globally.

​

SIOP's work has contributed to major advances in:

​

• Risk-adapted treatment planning.

• Nephron-sparing surgery where appropriate.

• Improved pathology classification.

• Better imaging protocols.

• Reduced treatment-related toxicity.

• International pathology review.

• Molecular risk stratification.

• Long-term survivorship care.

• International clinical trial collaboration.

• Quality assurance in pediatric renal oncology.

 

These achievements have helped establish Wilms tumor as one of the most successfully treated childhood solid tumours while continuing to improve long-term outcomes for survivors.

​

The SIOP Renal Tumour Study Group (RTSG)

​

At the heart of SIOP's contribution to Wilms tumor care is the SIOP Renal Tumour Study Group (RTSG), one of the world's leading collaborative research groups dedicated exclusively to pediatric renal tumours. Bringing together internationally recognised experts in pediatric oncology, surgery, pathology, radiology, radiation oncology, molecular biology, genetics, and epidemiology, the RTSG provides scientific leadership for many of the world's most influential Wilms tumor studies.

​

The primary objective of the RTSG is to continually improve outcomes for children with kidney tumours through collaborative clinical research. Its work focuses not only on increasing survival but also on reducing treatment-related complications, preserving kidney function, minimising long-term side effects, and improving quality of life for survivors. This philosophy reflects the modern understanding that successful cancer treatment should extend beyond cure alone to include lifelong health and wellbeing.

​

The RTSG has coordinated numerous landmark international studies that have shaped the management of Wilms tumor across Europe and many other parts of the world. These studies have examined virtually every aspect of care, including:

​

• Chemotherapy optimisation.

• Surgical timing and techniques.

• Nephron-sparing surgery.

• Pathology classification.

• Tumour staging.

• Molecular biomarkers.

• Imaging standards.

• Radiation therapy.

• Relapsed Wilms tumor.

• Bilateral Wilms tumor.

• High-risk histological subtypes.

• Survivorship and long-term follow-up.

 

One of the group's most significant achievements has been demonstrating how treatment intensity can be tailored according to tumour biology and individual patient risk. By identifying children who require less intensive therapy and those who may benefit from more aggressive treatment, the RTSG has helped improve survival while reducing unnecessary exposure to chemotherapy and radiation, thereby lowering the risk of long-term complications.

​

The RTSG also serves as a model for international scientific collaboration. By combining expertise from multiple countries, healthcare systems, and academic institutions, it enables researchers to study larger patient populations than would be possible within any single nation. This collaborative approach has accelerated scientific discovery, improved evidence quality, and contributed to internationally recognised standards of care that continue to influence pediatric oncology practice around the world.

​

The Wilms Cancer Foundation strongly supports the principles underpinning the RTSG's work. Through its educational programmes, healthcare professional resources, international partnerships, and knowledge translation initiatives, the Foundation helps extend the impact of this research beyond specialist centres, making evidence-based information more accessible to families, healthcare professionals, students, and policymakers worldwide. By promoting awareness of RTSG research and supporting educational activities aligned with its objectives, the Foundation contributes to the wider dissemination of scientific knowledge and reinforces the importance of international collaboration in improving outcomes for every child diagnosed with Wilms tumor.

​

​

Clinical Research, Treatment Protocols, Education & International Leadership

​​​

SIOP Clinical Trials and International Research

​

Scientific research lies at the heart of SIOP's mission to improve childhood cancer outcomes. Throughout its history, the organisation has coordinated some of the world's most influential international clinical studies in pediatric oncology, many of which have directly transformed the management of Wilms tumor.

​

Unlike research conducted within a single country or institution, SIOP's international collaborative model allows researchers to study thousands of patients from diverse healthcare systems. This produces stronger scientific evidence, improves understanding of rare disease subtypes, accelerates innovation, and helps establish internationally recognised standards of care.

​

For Wilms tumor, successive SIOP clinical studies have examined virtually every aspect of patient management, including diagnosis, imaging, chemotherapy, surgery, pathology, radiotherapy, relapse management, survivorship, and molecular biology. The knowledge generated through these studies has helped clinicians better understand which children require more intensive treatment and which can safely receive less intensive therapy without compromising cure rates.

One of the defining strengths of SIOP research is its philosophy of continually balancing treatment effectiveness with long-term quality of life. While improving survival remains the primary objective, reducing unnecessary treatment-related toxicity has become equally important as increasing numbers of children survive well into adulthood.

​

Research priorities continue to evolve alongside advances in medicine and now include:

​

• Precision medicine

• Molecular diagnostics

• Tumour genomics

• Artificial intelligence

• Digital pathology

• Biomarker discovery

• International data sharing

• Survivorship research

• Fertility preservation

• Quality-of-life outcomes

• Nephron-sparing surgery

• Global health implementation science

 

Each new study builds upon decades of previous research, ensuring that treatment recommendations continue to reflect the latest scientific evidence.

 

Landmark SIOP Wilms Tumor Studies

 

Over the past several decades, SIOP has coordinated multiple landmark international studies that have significantly influenced modern treatment strategies for Wilms tumor.

​

Among the most influential have been:

 

SIOP 9

Helped establish important evidence supporting pre-operative chemotherapy while improving understanding of surgical outcomes.

​

SIOP 93-01

Refined treatment approaches based on tumour stage and histology while further reducing treatment-related complications.

​

SIOP 2001 

One of the largest and most influential international Wilms tumor studies ever undertaken.

 

Major achievements included:

​

• Improved pathology classification.

• Better risk stratification.

• More individualised chemotherapy.

• Reduced overtreatment.

• Enhanced multidisciplinary collaboration.

• Greater international standardisation.

 

UMBRELLA Protocol​

The UMBRELLA protocol represents the latest evolution of international Wilms tumor research within the SIOP Renal Tumour Study Group. Rather than functioning as a single clinical trial, UMBRELLA serves as an integrated international research platform that combines:

​

• Clinical care

• Molecular diagnostics

• Pathology review

• Biobanking

• Translational research

• Biomarker development

• Future clinical trials

 

This approach allows scientific discoveries to move more rapidly from laboratory research into everyday clinical practice.

​

Precision Medicine and Future Research

 

The future of pediatric renal oncology is increasingly being shaped by precision medicine. Historically, treatment decisions were based primarily upon:

​

• Stage

• Histology

• Age

• Tumour size

 

Today, researchers are increasingly incorporating:

​

• Molecular biomarkers

• Genetic mutations

• Chromosomal abnormalities

• Gene expression

• Tumour biology

• Artificial intelligence

 

This allows clinicians to understand not only where a tumour has spread but also how it behaves biologically.

​

Research continues into:

​

• WT1 mutations

• TP53 abnormalities

• 1q gain

• Loss of heterozygosity

• MicroRNA profiles

• Circulating tumour DNA

• Liquid biopsy

• AI-assisted pathology

• Machine learning prediction models

 

The objective is straightforward:

​

Treat every child according to the biology of their tumour rather than applying identical treatment to every patient.

​

SIOP Treatment Protocols

​

One of SIOP's greatest contributions has been the development of internationally recognised treatment protocols that provide evidence-based guidance for healthcare professionals managing children with Wilms tumor. These protocols help ensure consistency of care across hospitals while allowing treatment to be adapted according to individual patient characteristics.

​

Treatment recommendations typically consider:

​

• Age

• Tumour stage

• Histology

• Molecular risk

• Bilateral disease

• Metastatic disease

• Treatment response

• Surgical findings

 

The protocols also provide guidance for:

​

• Chemotherapy selection

• Surgical timing

• Radiotherapy

• Pathology review

• Imaging

• Follow-up

• Long-term surveillance

 

These continually evolve as new scientific evidence becomes available.

​

Pre-operative Chemotherapy

​

Perhaps the most recognised feature of SIOP treatment protocols is the recommendation that most children receive chemotherapy before surgery.

Potential advantages include:

​

• Tumour shrinkage.

• Lower risk of tumour rupture.

• Easier surgery.

• Better preservation of healthy kidney tissue.

• Improved surgical planning.

• Reduced operative complications.

 

This differs from the historical Children's Oncology Group approach, where surgery has often been performed before chemotherapy.

Importantly, both treatment philosophies are supported by decades of scientific evidence and continue to contribute to excellent survival rates. Ongoing collaboration between international research groups continues to refine these approaches as new evidence emerges.

​

Multidisciplinary Care

​

SIOP strongly advocates multidisciplinary care.

​

Every child should ideally be managed by a specialist team including:

​

• Pediatric oncologists

• Pediatric surgeons

• Pediatric nephrologists

• Radiologists

• Pathologists

• Radiation oncologists

• Oncology nurses

• Nutritionists

• Clinical psychologists

• Physiotherapists

• Social workers

• Survivorship specialists

 

This collaborative approach improves treatment planning, reduces complications, enhances communication, and supports families throughout every stage of care.

​

Education and Healthcare Professional Development

​

Education has always been one of SIOP's defining strengths.

​

Scientific advances can only improve patient outcomes if healthcare professionals have access to the latest evidence and opportunities for continuing education.

​

SIOP supports lifelong learning through:

​

• International congresses

• Regional conferences

• Scientific workshops

• Educational webinars

• Specialist working groups

• Online learning

• Consensus meetings

• Guideline development

• Mentorship

• International networking

 

These initiatives allow clinicians from every region of the world to exchange knowledge, discuss challenging cases, and learn directly from internationally recognised experts.

​

Supporting Healthcare Professionals Worldwide

​

One of SIOP's most important roles is supporting clinicians working in countries with limited pediatric oncology resources. Education initiatives include:

​

• Practical treatment guidance.

• Surgical education.

• Pathology training.

• Imaging interpretation.

• Nursing education.

• Nutrition support.

• Supportive care.

• Survivorship programmes.

• Research methodology.

• Clinical trial participation.

 

This capacity-building approach helps strengthen local healthcare systems while reducing inequalities in childhood cancer care.

​

SIOP Congresses

​

SIOP's annual congress is recognised as one of the world's leading pediatric oncology scientific meetings. Thousands of delegates attend from across the globe, including:

​

• Pediatric oncologists

• Surgeons

• Radiation oncologists

• Nurses

• Researchers

• Pathologists

• Epidemiologists

• Psychologists

• Survivorship specialists

• Patient advocates

• Non-governmental organisations

 

The congress provides opportunities to:

​

• Present new research.

• Launch clinical studies.

• Review treatment guidelines.

• Discuss difficult cases.

• Build international collaborations.

• Share innovations.

• Promote multidisciplinary care.

• Strengthen global partnerships.

 

For the Wilms Cancer Foundation, these meetings provide an important opportunity to support scientific exchange, promote evidence-based education, engage with international experts, and contribute to discussions focused on improving outcomes for children with Wilms tumor worldwide.

​

The Wilms Cancer Foundation's Support for SIOP Education

​

The Wilms Cancer Foundation is committed to strengthening SIOP's educational mission by actively promoting its work and supporting initiatives that improve knowledge sharing throughout the international pediatric oncology community.

​

This support includes:

​

• Sponsorship of Wilms tumor-focused scientific conferences and educational events.

• Promotion of SIOP educational programmes through the Foundation's international communication platforms.

• Participation in international meetings and congresses.

• Dissemination of evidence-based educational resources.

• Supporting healthcare professional engagement.

• Raising awareness of SIOP clinical guidance and research.

• Collaborating on international educational initiatives where opportunities exist.

• Supporting activities aligned with WHO and GICC priorities.

• Encouraging multidisciplinary collaboration across the global Wilms tumor community.

 

The Foundation views SIOP not simply as an international scientific society, but as an essential partner in advancing global childhood kidney cancer care. By helping extend the reach of SIOP's educational activities and promoting international collaboration, the Foundation contributes to a shared vision of ensuring that every child diagnosed with Wilms tumor has access to the highest possible standard of evidence-based care.

​​​

 

 

Global Leadership, WHO & GICC Alignment, Partnership with the Wilms Cancer Foundation, and the Future of International Collaboration Supporting Low- and Middle-Income Countries (LMICs)

​

Although remarkable progress has been made in the treatment of Wilms tumor in many high-income countries, significant disparities remain in access to diagnosis, treatment, surgery, pathology, radiotherapy, supportive care, and survivorship services throughout much of the world. Children living in many low- and middle-income countries (LMICs) continue to face substantial barriers that can delay diagnosis, interrupt treatment, and ultimately reduce survival.

​

Recognising these challenges, SIOP has made global health equity one of its central priorities. Through its international networks, specialist working groups, educational programmes, regional partnerships, and research collaborations, the organisation supports efforts to strengthen childhood cancer services in countries where resources are limited. Rather than applying a single model of care to every healthcare system, SIOP promotes practical, evidence-based approaches that can be adapted to local circumstances while maintaining the highest possible standards of patient care.

​

These initiatives focus on strengthening every stage of the childhood cancer pathway, including:

​

​

• Earlier recognition of childhood cancer symptoms.

• Faster referral to specialist centres.

• Improved diagnostic accuracy.

• Safer surgery.

• Greater access to essential chemotherapy.

• Appropriate use of radiotherapy.

• Better pathology services.

• Supportive care and infection management.

• Survivorship and long-term follow-up.

• Healthcare workforce development.

• Data collection and cancer registries.

 

By working alongside national governments, hospitals, universities, professional societies, charitable organisations, and international agencies, SIOP helps build sustainable pediatric oncology programmes that continue to improve long after individual projects have concluded.

​

For children diagnosed with Wilms tumor, these improvements can mean the difference between delayed diagnosis and timely treatment, between fragmented care and coordinated multidisciplinary management, and ultimately between poor outcomes and long-term survival.

​

Building Sustainable Healthcare Capacity

​

Improving childhood cancer outcomes requires more than introducing new medicines or treatment protocols. Sustainable improvements depend upon developing healthcare systems that can consistently deliver safe, high-quality care over many years.

​

SIOP therefore places considerable emphasis on healthcare capacity building, recognising that long-term success depends upon strengthening local expertise rather than relying solely on external support.

​

Capacity-building initiatives may include:

​

• Training pediatric oncologists.

• Developing specialist nursing programmes.

• Supporting pediatric surgeons.

• Improving pathology services.

• Expanding diagnostic imaging.

• Strengthening multidisciplinary team working.

• Developing clinical leadership.

• Supporting research infrastructure.

• Improving quality assurance.

• Establishing survivorship services.

 

This approach helps countries become increasingly self-sufficient while ensuring that children continue to benefit from internationally recognised standards of care.

​

The Wilms Cancer Foundation shares this philosophy through its Global Wilms Tumor Initiative™ (GWTI), which seeks to support healthcare professionals, families, researchers, and governments by making specialist Wilms tumor knowledge more widely accessible through education, international collaboration, multilingual resources, and digital innovation.

​

SIOP and the World Health Organization (WHO)

​

The objectives of SIOP closely complement those of the World Health Organization in improving childhood cancer outcomes worldwide. While WHO provides global public health leadership, policy development, and strategic direction, SIOP contributes scientific expertise, clinical research, professional education, and multidisciplinary collaboration.

​

Together, these complementary roles help strengthen childhood cancer care across multiple levels of healthcare systems.

​

Areas of shared focus include:

​

• Early diagnosis.

• Timely referral.

• Access to effective treatment.

• Multidisciplinary care.

• Healthcare workforce development.

• Clinical education.

• Evidence-based medicine.

• Quality improvement.

• Long-term survivorship.

• Reducing global inequalities.

• Sustainable healthcare systems.

• International collaboration.

 

For Wilms tumor specifically, these shared priorities contribute to improving outcomes by ensuring that children receive earlier diagnosis, more appropriate treatment, better supportive care, and ongoing long-term follow-up regardless of where they live.

​

Supporting the WHO Global Initiative for Childhood Cancer (GICC)

​

Launched by the World Health Organization in partnership with leading international organisations, the Global Initiative for Childhood Cancer (GICC) aims to increase global childhood cancer survival while reducing inequalities between countries.

​

Its ambition of achieving significantly improved survival through the implementation of the CureAll Framework aligns closely with SIOP's long-standing commitment to improving access to high-quality pediatric oncology services worldwide.

​

The CureAll Framework focuses on four interconnected pillars:

​

Centres of Excellence

Developing specialist treatment centres capable of delivering multidisciplinary childhood cancer care.

​

Universal Health Coverage

Ensuring children can access diagnosis, treatment, medicines, surgery, radiotherapy, and supportive care without experiencing catastrophic financial hardship.

 

Treatment Regimens

Providing safe, evidence-based treatment protocols adapted to local healthcare systems.

 

Evaluation and Monitoring

Strengthening cancer registries, quality assurance programmes, data collection, and continuous improvement.

 

Supporting these pillars are three enabling elements:

​

• Advocacy

• Financing

• Governance

 

Although SIOP and WHO have distinct organisational roles, both recognise that improving childhood cancer survival requires coordinated action across governments, healthcare professionals, academic institutions, charities, patient organisations, and international partners.

​

A Shared Commitment to Global Childhood Cancer Equity

​

Reducing inequalities in childhood cancer care has become one of the defining priorities of modern pediatric oncology.

​

While survival for Wilms tumor now exceeds 90% in many high-income countries, outcomes remain substantially lower in numerous resource-constrained settings because of delayed diagnosis, treatment abandonment, limited access to specialist surgery, shortages of chemotherapy, inadequate pathology services, and insufficient long-term follow-up.

​

SIOP actively supports initiatives designed to address these challenges through:

​

• International collaboration.

• Healthcare professional education.

• Clinical research.

• Capacity building.

• Evidence-based treatment guidance.

• Sustainable healthcare development.

• Regional partnerships.

• Scientific exchange.

 

The Wilms Cancer Foundation similarly recognises that improving outcomes requires far more than producing educational resources. Sustainable change depends upon supporting healthcare professionals, empowering families, strengthening international partnerships, encouraging governments, and promoting evidence-based practice across every stage of the childhood cancer journey.

​

Together, these complementary approaches contribute to a broader international effort to ensure that geography is no longer a determining factor in a child's chance of surviving Wilms tumor.

​

The Wilms Cancer Foundation's Partnership with SIOP

​

The Wilms Cancer Foundation values its growing relationship with the International Society of Paediatric Oncology and is committed to supporting SIOP's international mission to improve childhood cancer outcomes through education, collaboration, and the dissemination of evidence-based knowledge.

​

As a specialist organisation dedicated exclusively to Wilms tumor, the Foundation complements SIOP's scientific leadership by translating complex clinical evidence into practical resources that can be understood and used by parents, caregivers, healthcare professionals, students, researchers, policymakers, and advocacy organisations.

​

The Foundation's support for SIOP includes:

​

• Sponsorship of selected scientific and educational events.

• Participation in international conferences and congresses.

• Promotion of SIOP educational initiatives.

• Development of evidence-based educational literature.

• Production of multilingual patient information.

• International awareness campaigns.

• Healthcare professional engagement.

• Digital knowledge translation.

• Support for multidisciplinary collaboration.

• Promotion of international research.

• Sharing best practice.

• Supporting implementation of WHO and GICC priorities.

 

Rather than duplicating SIOP's work, the Foundation seeks to extend its reach by making specialist Wilms tumor knowledge more accessible to wider audiences around the world.

​

Complementing Scientific Excellence Through Education

​

Scientific discovery alone cannot improve outcomes unless knowledge reaches the people who need it most.

​

One of the Wilms Cancer Foundation's principal objectives is therefore to bridge the gap between research and everyday practice by translating complex medical evidence into clear, accessible educational resources.

​

Through initiatives including the Global Wilms Tumor Initiative™ (GWTI), the Wilms Tumor Knowledge Index™ (WTKI), the Wilms Tumor WebApp, multilingual educational programmes, and international partnerships, the Foundation helps ensure that evidence generated through organisations such as SIOP can be more readily understood and applied by diverse audiences across different healthcare settings.

​

This knowledge translation supports:

​

• Parents and caregivers seeking trusted information.

• Healthcare professionals requiring educational resources.

• Students learning pediatric oncology.

• Researchers exploring current evidence.

• Advocacy organisations raising awareness.

• Governments developing childhood cancer strategies.

• International partners supporting healthcare capacity building.

By making specialist knowledge easier to access, the Foundation contributes to a global learning ecosystem that complements SIOP's scientific and educational leadership.

 

Looking Ahead: The Future of International Collaboration

​

The future of Wilms tumor care will increasingly depend upon international collaboration that extends beyond traditional research networks. Advances in molecular biology, artificial intelligence, digital health, precision medicine, and global knowledge sharing are creating new opportunities to improve diagnosis, personalise treatment, reduce long-term side effects, and strengthen healthcare systems worldwide.

​

SIOP will continue to play a central role in this evolution through international research, clinical leadership, professional education, and multidisciplinary collaboration. At the same time, organisations such as the Wilms Cancer Foundation can help accelerate the dissemination and practical application of this knowledge through innovative educational platforms, multilingual resources, and global awareness initiatives.

​

Looking ahead, opportunities for collaboration include:

​

• International webinar series.

• Joint educational literature.

• Digital learning platforms.

• AI-assisted educational tools.

• Global knowledge-sharing initiatives.

• Conference participation.

• Regional capacity-building programmes.

• Multilingual healthcare resources.

• Research dissemination.

• Public awareness campaigns.

• Support for WHO and GICC implementation.

• Expansion of educational initiatives into underserved regions.

 

Together, these efforts represent a shared commitment to ensuring that every child diagnosed with Wilms tumor—regardless of where they live—can benefit from the latest scientific knowledge, evidence-based treatment, and compassionate multidisciplinary care.​​​​​

​

Website: https://siop-online.org/ ​